Extraction of Antiepileptic Drugs from Oral Fluid Using ISOLUTE® SLE+ Prior to LC-MS/MS Analysis

This application note describes the extraction of neutral and zwitterionic antiepileptic drugs from fortified oral fluid using ISOLUTE® SLE+ in a 96-well plate format.




Figure 1. Structures of Carbamazepine Epoxide, Rufinamide and Gabapentine

Introduction

Antiepileptic drugs (AED) are prescribed to suppress seizures in epilepsy patients. A variety of different types of AEDs have been synthesized to pharmacologically address different types of epilepsy. The ability to therapeutically monitor these drugs in patients is necessary for maintaining optimal medical care and managing any adverse effects of the drug. A fast and clean extraction method is needed that works in a variety of biological matrices and affords a high throughput workflow. Here supported liquid extraction is demonstrated as an effective way to extract AEDs from neat oral fluid and oral fluid collected with commercial kits such as the QuantisalTM (Immunalysis) and Intercept[®] (OraSure Technologies) with good efficiency. The method was developed on a 96-well plate format to facilitate a high throughput workflow model.

ISOLUTE® SLE+ Supported Liquid Extraction plates and columns offer an efficient alternative to traditional liquid-liquid extraction (LLE) for bioanalytical sample preparation, providing high analyte recoveries, no emulsion formation, and significantly reduced sample preparation time.

Analytes

Tiagabine, Carbamazepine 10,11 epoxide, Oxcarbazepine, Gabapentin, Vigabatrin, Rufinamide and Felbamate

Sample Preparation Procedure

Format: ISOLUTE SLE+ 400 µL Supported Liquid Extraction Plate, part number 820-0400-P01

Sample Pre-treatment: Pipette neat oral fluid or buffered oral fluid (blank, calibrator and patient, (100 μL)) into a

container. Add Ammonium Acetate (5mM, pH 2.9, 250µL). Add up to 50 µL of internal standard.

Sample Processing: Load up to 400 μL of pre-treated oral fluid sample onto the ISOLUTE SLE+ 96-well plate. Apply a

short pulse of positive pressure or vacuum and allow samples to absorb for 5 minutes.

Analyte Elution: Elute analytes with methyl tert-butyl ether containing 1% (v/v) trifluoroacetic acid (conc) solution

 $(2 \times 700 \mu L)$. Allow sample to flow through by gravity and collect eluent. Apply positive pressure or vacuum as needed to facilitate a constant flow of approximately 1 mL/min (10-12 drops).

Post Extraction: Evaporate to dryness (45 °C for 15 mins) and reconstitute sample into mobile phase.

Additional Information: Oral fluid was tested as a neat solution and as a buffered solution using proprietary buffer

solutions provided by the Immunalysis Quantisal kit and the OraSure Intercept kit.



HPLC Conditions

Instrument: Agilent 1200 Liquid Handling System (Agilent Technologies, Berkshire, UK)

Column: Phenomenex Gemini C18, 150 mm x 4.6 mm (5 μm)

Mobile Phase: Solvent A: 5mM Ammonium Formate with 0.01% (v/v) Formic Acid

Solvent B: Methanol: Acetonitrile (50:50, v/v)

Gradient:

Step	Time (min)	Flow Rate (µL/min)	%A	%B
1	0.0	1000	70	30
2	0.50	1000	70	30
3	3.0	1000	30	70
4	4.0	1000	30	70
5	4.5	1000	70	30
6	7.5	1000	70	30

Mass Spectrometry Conditions

Applied Biosystems/MDS Sciex 4000 Q-Trap triple quadrupole mass spectrometer (Applied Biosystems, Foster City, CA.) equipped with a Turbo lonspray® interface for mass analysis.

Ionization Source Temperature: 700 °C

Analyte	MRM Transition	Declustering Potential (DP)	Collision Energy (CE)	Cell Exit Potential (CXP)
Gabapentine	172>154	40	25	16
Felbamate	178>117	40	25	16
Rufinamide	239>127	40	25	16
Oxcarbazepine	253>208	40	25	16
Tiagabine	376>247	40	25	16
Vigabatrine	130>70.9	40	25	16
Carbamazepine Epoxide	253>180	40	30	16

Table 1. MRM transitions for AED drugs in positive mode Turbo Ionspray.






Figure 2. Extracted ion chromatogram of antiepileptic drugs

Results and Discussion

Antiepileptic drug (AED) stock standards were prepared in methanol: acetone (80:20, v/v) at $100~\mu g/mL$ concentration. The parameters for LC-MS/MS analysis were identified and optimized using the stock solutions (**Figure 2**). The stock solutions were fortified into blank neat oral fluid matrix at final spiking concentrations of 20~ng/mL. Oral fluid was also collected using two different commercial kits to test effects of buffer solutions on analyte recovery. The two kits used were the Immunalysis Quantisal kit and the OraSure Intercept kit. The elution strategy utilizes methyl tert-butyl ether mixed with 1% concentrated trifluoroacetic acid (TFA) (v:v) to yield optimal recoveries. The addition of TFA to the extraction solvent seemed to increase overall recoveries from 5-10%.

An ion pairing pre-treatment strategy was found to be most effective for neutral AEDs. The pre-treatment strategy calls for 10 mM ammonium acetate to be added to the fortified matrix at a 1:2.5 (v:v) ratio. Recoveries for the AEDs using this pre-treatment strategy were good for all of the neutral AEDs in either neat or buffered oral fluid and substantially lower for the zwitterionic AEDs (**Figure 3**). The lower recovery for the gabapentin and vigabatrin was attributed to their acidic and basic functionality which maintains a charge on the molecule under acidic or basic pH. This constant charge increases the aqueous solubility of the zwitterionic AEDs and lowers their propensity for efficient elution with water immiscible organic solvents.






Figure 3. Plot of average recoveries for neutral and zwitterionic antiepileptic drugs (n=7) fortified into neat and buffered oral fluid at 20 ng/mL.

Ordering Information

Part Number	Description	Quantity
820-0400-P01	ISOLUTE® SLE+ 400 μ L Supported Liquid Extraction Plate	1
SD-9600-DHS-EU	Biotage® SPE Dry Sample Concentrator System 220/240 V	1
SD-9600-DHS-NA	Biotage® SPE Dry Sample Concentrator System 100/120 V	1
PPM-96	Biotage® Positive Pressure Manifold 96 position	1

For the latest application notes visit www.biotage.com

EUROPE

Main Office: +46 18 565900 Toll Free: +800 18 565710 Fax: +46 18 591922 Order Tel: +46 18 565710 Order Fax: +46 18 565705 order@biotage.com Support Tel: +46 18 56 59 11 Support Fax: + 46 18 56 57 11 eu-1-pointsupport@biotage.com

NORTH & LATIN AMERICA

Main Office: +1 704 654 4900 Toll Free: +1 800 446 4752 Fax: +1 704 654 4917 Order Tel: +1 704 654 4900 Order Fax: +1 434 296 8217 ordermailbox@biotage.com Support Tel: +1 800 446 4752 Outside US: +1 704 654 4900 us-1-pointsupport@biotage.com

JAPAN

Tel: +81 3 5627 3123 Fax: +81 3 5627 3121 jp_order@biotage.com jp-1-pointsupport@biotage.com

CHINA

Tel: +86 21 2898 6655 Fax: +86 21 2898 6153 cn_order@biotage.com cn-1-pointsupport@biotage.com

To locate a distributor, please visit our website at www.biotage.com

Part Number: AN811

© 2014 Biotage. All rights reserved. No material may be reproduced or published without the written permission of Biotage.

Information in this document is subject to change without notice and does not represent any commitment from Biotage. E&OE. Quantisal is a trademark of Immunalysis, Intercept is a registered trademark of OraSure Technologies. Other product and company names mentioned herein may be trademarks or registered trademarks and/or service marks of their respective owners, and are used only for explanation and to the owners' benefit, without intent to infringe. For more information visit www.biotage.com.

